Table 2. Liver lesions ablation rates.
| First author | Treatment | N of patients | Ablation 100% | Ablation 50–100% | Ablation <50% | Evaluation | Imaging |
|---|---|---|---|---|---|---|---|
| Leslie (22) | HIFU | 7 | 3 | 1 | 3 | Decreased enhancement | MRI |
| Zhou (23) | HIFU | 15 | 8 | 7 (partial) | 0 | n.s | n.s. |
| Park (26) | Sequential | 13 | 3 | 10 | 0 | Goldberg criteria | MRI or CT |
| Zhang (28) | HIFU | 39 | 21 | 18 | 0 | Decreased enhancement | MRI |
| Zhang (27) | Sequential | 6 | 6 | 0 | 0 | Captation | CT |
| Li (30) | TACE vs. TACE + HIFU | 44 (TACE + HIFU) | 12 | 20 | 12 | Decreased enhancement | MRI |
| Orsi (74) | HIFU | 23 | 21 | 2 | 0 | Decreased enhancement | MRI or CT or PET/CT |
| Numata (31) | HIFU | 21 | 18 | 3 | 0 | Decreased enhancement | 3D US, CT, MRI |
| Zhang (11) | HIFU | 27 | 27 | 0 | 0 | Necrosis | MRI |
| Jin (34) | TACE + HIFU | 73 | 33 | 40 | 0 | Decreased enhancement | MRI |
| Orgera (76) | HIFU | 8 (13 lesions) | 11 | 2 | 0 | Decreased enhancement /no FDG uptake | PET/CT or CT |
| Ng (35) | HIFU | 49 | 39 | 10 | 0 | absence of T2 hyperintensity | MRI |
| Xu (36) | HIFU/HIFU + TACE or PEI | 145 | 34 | 72 | 39 | Decreased enhancement | CT and/or MRI |
| Fukuda (33) | HIFU | 12 | 12 | 0 | 0 | Decreased enhancement | CT, MRI |
| Leslie (12) | HIFU | 31 | 28 | 3 | 0 | Tumor dimensions | MRI |
| Cheung (38) | Various* | 100 | 87 | 13 | 0 | n.s | MRI |
| Cheung (52) | HIFU | 1 | 1 | 0 | 0 | n.s. | CT |
| Cheung (37) | HIFU | 1 | 0 | 1 | 0 | Necrosis | MRI |
| Cheung (44) | HIFU vs. TACE | 10 (HIFU) | 9 | 1 | 0 | Recist criteria | CT or MRI |
| Chan (43) | HIFU vs. RFA | 27 (HIFU) | 23 | 4 | 0 | Decreased enhancement/no T2 signal | CT or MRI |
| Wang (55) | TACE + HIFU | 12 | 10 | 0 | 0 | Decreased enhancement | CT or MRI |
| TACE + HIFU | 12 | 0 | 12 | 0 | Decreased enhancement | CT | |
| Cheung (50) | HIFU vs. TACE | 26 (HIFU) | 13 | 2 | 11 | n.s | CT or MRI |
| Chok (51) | HIFU vs. TACE | 21 (HIFU) | 0 | 3 | 7 | Necrosis in excised liver | MRI |
| Wu (19) | TACE vs. TACE + HIFU | 24 (TACE + HIFU) | 0 | 24 | 0 | Decreased enhancement | US, CT, MRI |
| Wu (54) | HIFU and TACE + HIFU | 55 | 0 | 55 | 0 | n.s | US, CT, MRI |
| Rossi (48) | HIFU | 1 | 0 | 1 | 0 | n.s | CT |
| Total | 803 | 420 | 304 | 72 |
*: HIFU as primary treatment (n=27); as bridging therapy before OLT (n=3); recurrence of HCC after TACE (n=41); HIFU after partial hepatectomy (n=28); HIFU after OLT (n=1). HIFU, high intensity focused ultrasound; TACE, trans arterial chemo embolization; PEI, percutaneous ethanol injection; OLT, orthotopic liver transplantation; HCC, hepatocellular carcinoma.